Analysis of the association between KIN17 expression and the clinical features/prognosis of epithelial ovarian cancer, and the effects of KIN17 in SKOV3 cells

Chen, Junyu; Xia, Yang; Peng, Yuanqing; Wu, Shan; Liu, Wei; Zhang, Haoxian; Yang, Zhaoyun; Zhao, Shuhua; Zhao, Lijing

doi:10.3892/ol.2021.12736

Cited by 14 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to univariate analysis and Kaplan-Meier survival analysis, multivariate Cox regression analysis suggested that KIN17 and the tumor stage were independent prognostic factors in EOC. However, there was no association between the localization (cytoplasm or nucleus) of KIN17 and the overall survival (64).…”

Section: Roles Of Kin17 In Cancer Cellsmentioning

confidence: 85%

Roles and regulatory mechanisms of KIN17 in cancers (Review)

Huang

Dai

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

KIN17, which is known as a DNA and RNA binding protein, is highly expressed in numerous types of human cancers and was discovered to participate in several vital cell behaviors, including DNA replication, damage repair, regulation of cell cycle and RNA processing. Furthermore, KIN17 is associated with cancer cell proliferation, migration, invasion and cell cycle regulation by regulating pathways including the p38 MAPK, NF-κB-Snail and TGF-β/Smad2 signaling pathways. In addition, knockdown of KIN17 was found to enhance the sensitivity of tumor cells to chemotherapeutic agents. Immunohistochemical analysis revealed that there were significant differences in the expression of KIN17 between cancer tissues and adjacent tissues. Both the Kaplan-Meier survival analysis and multivariate Cox regression analysis indicated that KIN17 is aberrantly high expressed in various tumor tissues and is also associated with poor prognosis in patients with various tumor types. Taken together, KIN17 has key roles in tumorigenesis and cancer development. Investigating the relationship between KIN17 and neoplasms will provide a vital theoretical basis for KIN17 to serve as a diagnostic and prognostic biomarker for cancer patients and as a potential target for cancer therapy.

show abstract

Section: Roles Of Kin17 In Cancer Cellsmentioning

confidence: 85%

Roles and regulatory mechanisms of KIN17 in cancers (Review)

Huang

Dai

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Finally, the slides were imaged using an Olympus optical microscope (BX51). The evaluation criteria were based on staining intensity and the proportion of positive tumour cells as previously described 26 . For staining intensity: 0 (no colour), 1 (light yellow), 2 (yellow brown), and 3 (brown).…”

Section: Methodsmentioning

confidence: 99%

“…The evaluation criteria were based on staining intensity and the proportion of positive tumour cells as previously described. 26 For staining intensity: 0 (no colour), 1 (light yellow), 2 (yellow brown), and 3 (brown). For the proportion of positive tumour cells: 0 (<5%), 1 (5%-25%), 2 (26%-50%), 3 (51%-75%), and 4 (>75%).…”

Section: Immunohistochemistrymentioning

confidence: 99%

PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma

Wang

Huang

et al. 2023

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Uterine corpus endometrial carcinoma (UCEC) is one of the most common malignancies in the female genital tract, with over 200,000 new cases diagnosed worldwide each year. 1,2 In recent years, the morbidity and mortality of UCEC have been increasing over time due to the increase in life expectancy of the population and the overall prevalence of obesity and metabolic syndrome, and the age of onset has been decreasing, posing a serious threat to women's health and lives. [3][4][5] Although we have made great progress in the treatment of

show abstract

“…Immunohistochemistry. Immunohistochemical (IHC) staining was performed as previously described (23). Briefly, after being fixed in 10% formalin at room temperature for 24 h, PCa samples or mouse tumour samples were embedded in paraffin and cut into 3-µm-thick sections.…”

Section: Methodsmentioning

confidence: 99%

HMGB1 promotes the development of castration‑resistant prostate cancer by regulating androgen receptor activation

Chen

Wang

et al. 2022

Oncol Rep

Self Cite

View full text Add to dashboard Cite

AR signalling pathway reactivation plays a key role in the development of castration-resistant prostate cancer (CRPC). High-mobility group protein B1 (HMGB1) is an important factor involved in the occurrence and development of a variety of tumours by regulating gene transcription. In the present study, the association between HMGB1 and prostate cancer (PCa) and the effects of HMGB1 on androgen receptor (AR) transcription and signalling pathway reactivation in PCa cells in vitro and in vivo were evaluated. A bioinformatics method was used to determine the mRNA expression level of HMGB1 in PCa specimens and its correlation with the mRNA expression of AR. Immunohistochemical staining was used to detect the expression of these proteins in clinical PCa samples. Reporter gene and ChIP assays were performed to determine the activity of AR and the effect of HMGB1 on the ability of AR to bind to the promoters of prostate specific antigen and transmembrane protease, serine 2. A bioluminescence resonance energy transfer assay was employed to observe the direct interaction between HMGB1 and AR protein. Additionally, a castrated nude mouse xenograft tumour model was established to verify the effect of HMGB1 on PCa. The results revealed that HMGB1 expression was significantly increased in PCa specimens, which may have a strong correlation with AR expression. Moreover, HMGB1 could reactivate the AR signalling pathway, directly interact with AR, and promote the development of CRPC in an androgen-independent manner. The results of the present study indicated that HMGB1 promoted the development of CRPC by interacting with AR, which inferred that decreasing the expression of HMGB1 may be a potential effective method for CRPC prevention and treatment.

show abstract

Analysis of the association between KIN17 expression and the clinical features/prognosis of epithelial ovarian cancer, and the effects of KIN17 in SKOV3 cells

Cited by 14 publications

References 26 publications

Roles and regulatory mechanisms of KIN17 in cancers (Review)

Roles and regulatory mechanisms of KIN17 in cancers (Review)

PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma

HMGB1 promotes the development of castration‑resistant prostate cancer by regulating androgen receptor activation

Contact Info

Product

Resources

About